https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:23:09 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/5-gzv-38fuu-european-regulation-of-advanced-therapies/ Thu, 08 Oct 2020 14:08:13 +0000 http://13.40.107.223/video/5-gzv-38fuu-european-regulation-of-advanced-therapies/ Aurélie Mahalatchimy, PhD, Aix-en-Provence, Provence-Alpes-Côte d’Azur, France, discusses European regulation of advanced therapies and medicinal products, highlighting CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/1q-j1irtyh0-cellular-therapies-from-academia-to-industry/ Thu, 08 Oct 2020 14:08:13 +0000 http://13.40.107.223/video/1q-j1irtyh0-cellular-therapies-from-academia-to-industry/ Jürgen Kuball, MD, PhD, Utrecht University, Utrecht University, Netherlands, discusses how cellular therapies are translated from academia to industrial partners and any challenges associated with this. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/bqgdtx36kco-meta-analysis-anti-bcma-car-t-in-rr-myeloma/ Thu, 08 Oct 2020 14:08:13 +0000 http://13.40.107.223/video/bqgdtx36kco-meta-analysis-anti-bcma-car-t-in-rr-myeloma/ Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from the meta-analysis evaluating the outcomes of anti-BCMA CAR T-cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/9euabsoorr4-real-world-efficacy-safety-data-car-t-in-dlbcl/ Thu, 08 Oct 2020 14:08:13 +0000 http://13.40.107.223/video/9euabsoorr4-real-world-efficacy-safety-data-car-t-in-dlbcl/ Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory diffuse large B-Cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/kzshhs-upwq-the-potential-of-gene-edited-effector-cell-therapy/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/kzshhs-upwq-the-potential-of-gene-edited-effector-cell-therapy/ Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discusses gene-edited effector cell therapy, and its potential to improve the outcomes of T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/uwq5dli8vns-challenges-associated-with-car-t-cell-production/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/uwq5dli8vns-challenges-associated-with-car-t-cell-production/ Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses challenges associated with CAR T-cell production. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/ddxi36iknoo-challenges-associated-with-implementing-mscs-into-routine-practice/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/ddxi36iknoo-challenges-associated-with-implementing-mscs-into-routine-practice/ Francesco Dazzi, MD, PhD, King’s College Hospital NHS Foundation Trust, London, UK, outlines some of the challenges associated with implementing mesenchymal stem cells (MSCs) into treatment strategies and discusses the exploitation of apoptotic cells in order to generate the necessary regeneration signals. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/icydido0irw-gene-editing-legal-and-ethical-considerations/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/icydido0irw-gene-editing-legal-and-ethical-considerations/ Aurélie Mahalatchimy, PhD, Aix-en-Provence, Provence-Alpes-Côte d’Azur, France, discusses legal and ethical considerations surrounding gene editing. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/gq4mfx-wguw-gamma-delta-t-cell-therapy/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/gq4mfx-wguw-gamma-delta-t-cell-therapy/ Jürgen Kuball, MD, PhD, Utrecht University, Utrecht University, Netherlands, talks about gamma delta T-cell therapy and the potential advantages of its use. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/_abzty1a2k0-future-of-anti-bcma-car-t-cell-therapy-in-myeloma/ Thu, 08 Oct 2020 14:08:12 +0000 http://13.40.107.223/video/_abzty1a2k0-future-of-anti-bcma-car-t-cell-therapy-in-myeloma/ Noopur Raje, MD, Massachussetts General Hospital, Boston, MA, discusses areas of improvement in anti-BCMA CAR T-cell therapy in multiple myeloma, including evaluating the durability of response to CAR T-cell therapy, as well as the use of off-the-shelf allogeneic CAR-T. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>